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With the broadening availability of tools 
and methods, researchers have to define 
the most efficient binder applicable to the 
method and approach they have selected. 
These applications are carried out under 
different experimental conditions, which 
affect the choice of affinity reagent used. 
For example, binders can be either in 
solution or immobilized to a solid phase, 
and target proteins may be present either 
in a native, conformationally folded 
form or in a denatured state. To compare 
affinity reagents and decide upon the most 
appropriate one, users need comprehensive 
information regarding each reagent. 
Currently, multiple sources of information 
exist, including commercial catalogs of 
antibodies, portals centralizing affinity-
reagent properties from various sources 
and experimental results published in the 
literature describing the successful use of 
a binder in a specific application. Large-
scale production initiatives also add other 
sources such as validation and quality-
control results from production centers 
and independent quality assessment 
laboratories (such as the Antibodypedia 
portal; http://www.antibodypedia.org/). 
Even so, the available information may be 
incomplete; for example, the identification 
of a protein belonging to a particular family 
using a given antibody may be reported 
with no information concerning the 
assessment of possible cross-reactivity of 
the antibody with other family members. 
Existing information may also be biased by 
unsubstantiated reports from a commercial 
producer. Furthermore, data may appear 
contradictory at first glance, owing to 
a lack of precision in target or sample 
descriptions.
The purpose of MIAPAR is to permit the 
reliable identification of affinity reagent–
target–application triples. A binder is 
designed and produced for the detection of 
a particular target protein or peptide, often 
within a complex mixture. For maximum 
benefit of potential users, reporting of data 
about such a protein binder must describe 
(or reference) both its intended target and 
its qualities as a molecular tool. Ideally, such 
a description should include: (i) affinity 
reagent (and target) production processes, 
which may influence the characteristics of 
the binder and permit the unambiguous 
identification of the molecules; (ii) 
properties of the reagent as a binding 
tool, including its specificity, affinity, 
binding kinetics and cross-reactivity; 
(iii) the use of the reagent in applications 
(that is, compatibility with experimental 
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Minimum information about a 
protein affinity reagent (MIAPAR)
To the Editor:
We wish to alert your readers to MIAPAR, 
the minimum information about a protein 
affinity reagent. This is a proposal developed 
within the community as an important first 
step in formalizing standards in reporting 
the production and properties of protein 
binding reagents, such as antibodies, 
developed and sold for the identification 
and detection of specific proteins present 
in biological samples. It defines a checklist 
of required information, intended for use 
by producers of affinity reagents, quality-
control laboratories, users and databases 
(Supplementary Table 1). We envision 
that both commercial and freely available 
affinity reagents, as well as published 
studies using these reagents, could include 
a MIAPAR-compliant document describing 
the product’s properties with every available 
binding partner. This would enable the 
user or reader to make a fully informed 
evaluation of the validity of conclusions 
drawn using this reagent (Fig. 1). 
Supplementary Table 2 shows an 
example of a MIAPAR-compliant 
document, which could be derived 
from the information supplied in a 
single publication using the workflow 
summarized in Supplementary Figure 1.
Affinity reagents serve various roles in 
experimental studies. These include protein 
sample identification and detection; protein 
capture for isolation, purification and 
quantification; and functional studies. The 
choice of an applicable molecular tool is 
conditioned by the experimental objectives 
and the chosen approaches and methods. 
This has led to a widening of the range of 
molecules being used as affinity reagents 
(Table 1 and ref. 1). The best established 
are ‘natural’ polyclonal and monoclonal 
antibodies; however, an expanding range of 
recombinant constructs are now available, 
including single-chain variable fragments 
(scFvs), single-domain antibody fragments 
and diabodies. More recently, alternative 
affinity reagents have been developed, the 
biophysical properties of which present 
advantages in specific applications. They 
include protein scaffolds, such as fibronectin, 
lipocalins and ankyrin and armadillo repeat 
domains, and nucleic acid aptamers. These 
reagents are used in a growing range of 
experimental methods, including enzyme-
linked immunosorbent assay (ELISA), 
western blotting, immunohistochemistry, 
affinity chromatography and 
immunoprecipitation (Table 2).
At the same time, the systematic 
characterization of complete proteomes 
has led to an increase in the scale on 
which affinity reagents are produced. 
Several ambitious projects aim to 
develop systematic affinity-reagent 
collections. In Europe, they include the 
EU ProteomeBinders consortium1, the 
Human Protein Resource and Human 
Protein Atlas2 and the Antibody Factory3. 
In the United States, the National Cancer 
Institute (Bethesda, MD) has initiated the 
Clinical Proteomic Reagents Resource 
within the Clinical Proteomic Technologies 
Initiative for Cancer4. Globally, the Human 
Proteome Organization (HUPO) Human 
Antibody Initiative aims to promote 
and facilitate the use of antibodies for 
proteomics research, which embraces many 
of these activities (http://www.hupo.org/
research/hai), and the HUPO Proteomics 
Standards Initiative has developed PSI-
PAR, a global community standard format 
for the representation and exchange of 
protein affinity-reagent data5.
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the qualities of such reagents as molecular 
tools. Alternatively, a laboratory may 
produce one specific affinity reagent, either 
to develop a new production process or 
to meet research goals when there is no 
suitable commercial binder. In such a case, 
performed by academic or commercial 
producers or by systematic initiatives. In 
this case, a MIAPAR-compliant document 
could be used in the producer’s catalog 
or in public databases and repositories to 
describe accurately and unambiguously 
techniques and methods); and (iv) links 
to standardized protocols or experimental 
records that support the production 
process, the qualities of the binder as a tool 
and the claimed applications.
MIAPAR-compliant descriptions need to 
be kept up to date and relevant to the batch 
of material being made available. This may 
require a new document with every batch 
in the case of potentially variable reagents, 
such as polyclonal antibodies.
The underlying principle in MIAPAR 
is similar to that of other reporting 
guidelines developed as part of the HUPO 
Proteomics Standards Initiative (HUPO-
PSI)6. Required information is structured 
so as to allow entry into databases and 
enable useful querying and automated 
data analysis. This structure is designed 
to achieve comprehensive coverage and 
clarity. To provide unambiguous reports, 
MIAPAR recommends the use of standard 
naming conventions, such as database 
accession numbers, controlled vocabularies 
and the like, to describe entities and 
processes. Other important criteria in 
MIAPAR are sufficiency, meaning that 
a reader should be able to understand 
and evaluate the conclusions and their 
experimental corroboration, interpret the 
validity of the project and its outcome, 
and perform comparisons with similar 
projects; and practicality, meaning that the 
guidelines should not be so burdensome as 
to prohibit their widespread use.
The objective is not to describe in detail 
experimental results that will typically 
be recorded in databases or laboratory 
information management systems; nor 
is MIAPAR intended as a substitute for 
production protocols and procedures 
that are documented elsewhere, and its 
minimal information will not be sufficient 
to reproduce binder and target production 
or synthesis. Finally, the guidelines are 
not expected to be static. They have been 
assembled through consultations with a 
large number of experts and will evolve 
according to community requirements 
in the context of a rapidly developing 
technological framework. The MIAPAR 
document displayed on the HUPO-PSI 
website describes the most up-to-date 
version of the standard (http://www.psidev.
info/index.php?q=node/281); the content 
at the time of this publication can be found 
in the Supplementary Note.
MIAPAR is designed to be used for the 
reporting of several processes. The first is 
the production of new affinity reagents. 
This can be part of a large-scale activity 
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Figure 1  The scope of MIAPAR. MIAPAR-compliant reports will enable users to make informed choices 
when selecting from catalogs, databases or publications the binder best suited to a particular application. 
Table 1  Affinity-reagent types
Affinity reagent category Example
Immunoglobulin Full-length antibody (monoclonal or polyclonal)
Antibody fragment (e.g., Fab, scFv and related constructs including 
minibodies, diabodies, single VH or VL domains or nanobodies)
Protein scaffold Fibronectin
Ankyrin repeat
Armadillo repeat
Lipocalin (anticalin)
Affibody
Peptide ligand natural peptide
Synthetic peptide
Peptidomimetic
nucleic acid aptamer dnA aptamer
RnA aptamer
Small chemical entities natural product (secondary metabolite)
Synthetic product
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ontology may also be downloaded from 
the HUPO-PSI website (www.psidev.info/
index.php?q=node/281#cv). The use of a 
structured format and ontology to describe 
experiments and reagents has already aided 
the development of tools for selecting 
epitopes to raise affinity reagents9.
The MIAPAR guidelines have been 
developed within the affinity-reagent 
community in close collaboration 
with the HUPO-PSI work group on 
molecular interactions. As a standard for 
representation of affinity reagent–target 
interactions, MIAPAR extends the MIMIx 
guidelines for molecular interactions10 
with specific principles and practices 
appropriate for affinity reagents and their 
target molecules. As a standard to describe 
molecular tools, MIAPAR complements 
MIMIx with further characterization of 
the molecules involved, their method of 
production and their binding properties, 
and it further documents the use of the 
binders in experimental applications.
Within MIAPAR, information 
regarding experiments is limited to that 
which is essential for documenting the 
properties of the binder as a molecular 
tool. When required, more complete 
descriptions should be provided using 
ontologies for describing entities, processes 
and conditions is strongly recommended 
for MIAPAR documents. Regarding 
molecules, they may be identified by a 
database accession number from a public 
database, such as UniProtKB (http://www.
uniprot.org) for proteins and Ensembl 
(http://www.ensembl.org) or Entrez Gene 
(http://www.ncbi.nlm.nih.gov/gene/) for 
genes. The PSI-PAR controlled vocabulary 
under development (see below) provides a 
list of recommended databases and unified 
names for these resources.
A number of controlled vocabularies are 
available in the Open Biomedical Ontologies 
Foundry (http://www.obofoundry.org/)7 
and may be used to describe proteins, 
tissues, diseases and molecular interactions, 
including protein affinity interactions. A 
controlled vocabulary is currently being 
developed (PAR) to cover specifically 
protein affinity reagents, including terms 
not described in existing controlled 
vocabularies5. This is based on the molecular 
interactions vocabulary (MI) maintained 
as part of the HUPO-PSI. A draft version 
is available online through the European 
Bionformatics Institute ontology lookup 
service (http://www.ebi.ac.uk/ontology-
lookup/browse.do?ontName=PAR)8. The 
the MIAPAR document can complement 
the scientific publication describing the 
binder and provide a checklist for the 
author to work with during manuscript 
preparation. As reagents pass through 
quality-control procedures, an initial 
MIAPAR document could be updated 
with the corresponding reagent quality 
reports produced by laboratories charged 
with independent characterization and 
evaluation of available affinity reagents. 
Finally, when the binder is used in a 
specific experiment, such as protein 
identification in tissue samples, a reference 
to the corresponding MIAPAR document 
in the paper reporting the experiment 
would allow unique identification of the 
binder used and a clear understanding of 
both the strengths and the limitations of 
that protein identification. This process 
could also lead to an update of the 
MIAPAR document with the report of a 
successful experimental use of the binder 
in a particular application.
Whereas MIAPAR provides a list of 
descriptive items to document a binder 
uniquely and unambiguously, it does 
not define terms to be used to fill in the 
descriptions. Use of database accession 
numbers, controlled vocabularies and 
Table 2  Assay types and associated reagent states
Assay class Assay type Affinity reagent state Target state
Gels and blots Immunoblot (western blot) In solution denatured
Purification Affinity chromatography
Immunoprecipitation
Bound to solid phase
In solution
In solution, native folding
In solution, native folding
Staining Immunohistochemistry
Live cell imaging
In solution
In solution
Fixed (cross-linked)
native folding
Sorting and counting Fluorescence activated cell sorting
Magnetic cell sorting
In solution
In solution
Membrane bound, native folding
Membrane bound, native folding
Assays Radioimmunoassay Capture binder: in solution
detection: in solution
native folding (sometimes denatured)
Sandwich eLISA-type Capture binder: solid phase
detection: in solution
native folding (sometimes denatured)
Competitive eLISA-type Various configurations In solution, native folding
Affinity determination (SPR, QCM, etc.) In solution or bound to surface Bound to surface or in solution
Arrays Protein arrays no binder Bait: bound to surface
Prey: in solution
Antibody arrays Capture: solid phase In solution, native folding
Antibody arrays with sandwich Capture: solid phase
detection: in solution with other binders
In solution, native folding
Reverse phase arrays In solution Surface immobilized
Bead assays Single bead assays Capture: solid phase, bound to bead
detection: in solution
In solution, native folding
Multiplex bead assays Capture: solid phase, bound to bead
detection: in solution with other binders
In solution, native folding
Therapeutics Tumor therapy: tumor targeting Administered to mammalia Cell surface receptor, native folding
Tumor therapy: toxin neutralization Administered to mammalia native folding
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and experimental applications of affinity 
reagents emerge. There is still considerable 
scope for discussion of which characteristics 
of binders should be documented to 
support their efficient use in a wide range 
of experimental settings. Suggestions from 
the community are encouraged and will be 
collected and published on the PSI-PAR 
HUPO-PSI website (http://www.psidev.
info/index.php?q=node/281). We encourage 
binder producers and users to promote 
compliance with MIAPAR in the interests of 
the entire community.
Note: Supplementary information is available on the 
Nature Biotechnology website.
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other relevant guidelines; for instance, 
the immunohistochemical application 
in our example MIAPAR document 
(Supplementary Table 2) could be 
described more fully using the ‘minimum 
information specification for in situ 
hybridization and immunohistochemistry 
experiments’ (MISFISHIE) guidelines11. 
The Minimum Information for Biological 
and Biomedical Investigations project12 
is working to manage all such guidelines 
through a central repository of standards, 
providing a single entry point for users 
of guidelines and ensuring that these 
standards are complementary and 
nonoverlapping. 
MIAPAR has been developed to facilitate 
the sharing of data about affinity reagents 
within the scientific community. It does 
not dictate a specific format for reporting 
information but rather provides a checklist 
of the information which should be 
included somewhere within such a report. 
It is also a first stage toward the design of a 
data model and information infrastructure 
associated with the affinity-reagents field. 
In particular, an XML exchange format 
based on PSI-MI XML2.5 (refs. 6,13) and 
associated controlled vocabulary are now 
available5, and MIAPAR-compliant data 
maps to the PSI-PAR XML schema. Plans 
have also been made to adapt the IntAct14 
database to support the management of 
affinity-reagent data. The current MIAPAR 
guidelines serve as a basis for the design of a 
more complete knowledge model to be used 
for information exploitation and inference.
We recognize that these reporting 
guidelines are addressed to a somewhat 
different audience than most, in that the 
majority of available agents, particularly 
antibodies, are produced and sold by 
commercial companies. It is hoped that 
researchers will use these guidelines 
as leverage to request that companies 
supply MIAPAR-compliant data with 
each purchase, thus providing clear and 
consistent information about the quality of 
binding agents. Although it is difficult to 
see how this could be anything other than 
a voluntary agreement, we hope that once 
this commitment is made by a critical mass 
of manufacturers, both commercial and 
nonprofit, it will become standard practice.
We anticipate that MIAPAR will be updated 
as other binder types, production methods 
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